GlassScriptPhysician profile
John W Sawvel
NPI 1780682146
$1,400.47
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
See the full distribution for Neuromusculoskeletal Medicine & OMM
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $342 · 2021: $98.42 · 2022: $12.42 · 2023: $46.73 · 2024: $21.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $67.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $67.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $442.28 | 2019-2023 | Wegovy |
| Pfizer INC. | $230.91 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $178.31 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $142.07 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.99 | 2019-2020 | |
| Lilly USA, LLC | $58.35 | 2019-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $41.34 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.48 | 2019 | |
| Glaxosmithkline, LLC. | $39.08 | 2019 | |
| Abbott Laboratories | $35.72 | 2020-2021 | |
| Amgen INC. | $34.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.64 | 2019 | |
| Abbvie INC. | $21.23 | 2024 | |
| Allergan, INC. | $13.93 | 2019 | |
| Astellas Pharma US INC | $13.85 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $11.91 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sawvel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.